Home

PAUL C GRINT

CIK 1236548 · Chief Executive Officer · last filed 2024-07-18

PAUL C GRINT is a Chief Executive Officer who has filed 29 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for IKT, was dated Jul 18, 2024. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.7M across reported positions. 11 SEC filings were submitted jointly with ILLUMINA, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.73M

Companies

4

Total Filings

29

Lifetime Open-Market Net

-$1.46M

Filer Profile

Reported Address
7757 DOUGHILL COURT
SAN DIEGO, CA 92127
Related Filers
ILLUMINA, INC. — 11 joint filings, latest 2013-01-07
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IKT Director — $2.34 — $0 5 2024-07-18
Armata Pharmaceuticals, Inc. (APHB) Delisted Chief Executive Officer 43 — — $0 3 2017-12-12
Regulus Therapeutics Inc. (RGLS) Delisted President & CEO — $8.16 — $0 8 2017-02-23
ILMN Director 8,365 $206.45 $1.73M -$1.46M 13 2013-01-07

Recent Filings

29 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-07-18 IKT Grant (A) — $0 EDGAR
2023-07-05 IKT Grant (A) — $0 EDGAR
2022-06-28 IKT Grant (A) — $0 EDGAR
2021-06-29 IKT Grant (A) — $0 EDGAR
2020-12-29 IKT Grant (A) — $0 EDGAR
2017-12-12 Armata Pharmaceuticals, Inc. (APHB) Delisted Grant (A) +599 $371 EDGAR
2017-09-11 Armata Pharmaceuticals, Inc. (APHB) Delisted Grant (A) — $0 EDGAR
2017-02-23 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
2017-02-01 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
2016-10-07 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 29
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.